Lamotrigine Tablet, Film Coated, Extended Release
Product Images NDC 42291-445

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 42291-445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25mg (443 30 25mg)

This appears to be a product label for Lamotr, a medication that comes in extended-release tablets. The label cautions that the product is available for prescription only and is intended to be taken once a day. Each bottle contains 30 tablets. The rest of the text is not legible due to errors.*

FDA Label Image

50mg (444 30 50mg)

FDA Label Image

100mg (445 30 100mg)

FDA Label Image

200mg (446 30 200mg)

This appears to be a medication label for the drug Lamotrigine, which comes in the form of 200 mg extended-release tablets. It is intended to be taken once a day and caution is advised when dispensing the product. The label also includes a National Drug Code (NDC) and a phone number to contact the manufacturer (KARE.).*

FDA Label Image

250mg (447 30 250mg)

This appears to be a mixture of scrambled text and relevant information. The available text describes a tablet of "Lamotr" in a "Vority Product Dispensed" format. It is proposed for "Rx Only." The tablet is an "Extended-Release" medicine and should be taken "Once A Day." The tablet is cautioned to dispense, and the packaging consists of "30 Tablets." The rest of the text is non-readable or garbled.*

FDA Label Image

300mg (448 30 300mg)

The text appears to be a description of a medication named "Lamotrigine" which is extended-release tablets to be taken once daily, with a warning for its use. There is also a caution statement mentioned. However, there is not enough information available on its directions, usage, and side effects to provide a comprehensive description of the medication's benefits or drawbacks.*

FDA Label Image

Structural Formula (Lamotrigine Extended Release Tablets Usp 1)

FDA Label Image

Figure 1 (Lamotrigine Extended Release Tablets Usp 2)

This appears to be a chart or graph displaying the responder rates and improvement/worsening percentages for Lamotrigine Extended-Release and Placebo treatments, with numbers and percentages shown for each group. The text does not provide any further context or explanation.*

FDA Label Image

Figure 2 (Lamotrigine Extended Release Tablets Usp 3)

FDA Label Image

Q (Lamotrigine Extended Release Tablets Usp 4)

FDA Label Image

W (Lamotrigine Extended Release Tablets Usp 5)

FDA Label Image

R (Lamotrigine Extended Release Tablets Usp 6)

FDA Label Image

Y (Lamotrigine Extended Release Tablets Usp 7)

FDA Label Image

N (Lamotrigine Extended Release Tablets Usp 8)

FDA Label Image

B (Lamotrigine Extended Release Tablets Usp 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.